Wells Fargo’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1M | Sell |
55,757
-28,401
| -34% | -$569K | ﹤0.01% | 3728 |
|
|
2025
Q4 | $1.97M | Sell |
84,158
-41,811
| -33% | -$907K | ﹤0.01% | 3454 |
|
|
2025
Q3 | $2.51M | Buy |
125,969
+2,610
| +2% | +$46.9K | ﹤0.01% | 3161 |
|
|
2025
Q2 | $1.69M | Sell |
123,359
-93,119
| -43% | -$894K | ﹤0.01% | 3334 |
|
|
2025
Q1 | $2.39M | Sell |
216,478
-5,062
| -2% | -$54K | ﹤0.01% | 3027 |
|
|
2024
Q4 | $2.36M | Buy |
221,540
+5,801
| +3% | +$69.5K | ﹤0.01% | 3085 |
|
|
2024
Q3 | $2.74M | Sell |
215,739
-102
| -0% | -$1.51K | ﹤0.01% | 2819 |
|
|
2024
Q2 | $3.62M | Buy |
215,841
+3,561
| +2% | +$50.7K | ﹤0.01% | 2506 |
|
|
2024
Q1 | $3.18M | Sell |
212,280
-6,801
| -3% | -$111K | ﹤0.01% | 2609 |
|
|
2023
Q4 | $3.29M | Buy |
219,081
+2,548
| +1% | +$33.1K | ﹤0.01% | 2521 |
|
|
2023
Q3 | $3.03M | Sell |
216,533
-211,004
| -49% | -$3.39M | ﹤0.01% | 2467 |
|
|
2023
Q2 | $4.42M | Buy |
427,537
+3,997
| +0.9% | +$44.1K | ﹤0.01% | 2243 |
|
|
2023
Q1 | $3.91M | Buy |
423,540
+34,365
| +9% | +$316K | ﹤0.01% | 2317 |
|
|
2022
Q4 | $3.45M | Sell |
389,175
-3,963
| -1% | -$37.5K | ﹤0.01% | 2347 |
|
|
2022
Q3 | $3.27M | Buy |
393,138
+2,475
| +0.6% | +$20.5K | ﹤0.01% | 2319 |
|
|
2022
Q2 | $3.2M | Buy |
390,663
+136,671
| +54% | +$939K | ﹤0.01% | 2428 |
|
|
2022
Q1 | $2.21M | Buy |
253,992
+83,099
| +49% | +$648K | ﹤0.01% | 3200 |
|
|
2021
Q4 | $1.63M | Buy |
170,893
+36,456
| +27% | +$514K | ﹤0.01% | 3693 |
|
|
2021
Q3 | $2.26M | Buy |
134,437
+114,521
| +575% | +$1.82M | ﹤0.01% | 3557 |
|
|
2021
Q2 | $304K | Buy |
19,916
+15,663
| +368% | +$283K | ﹤0.01% | 4863 |
|
|
2021
Q1 | $83K | Sell |
4,253
-29,768
| -87% | -$632K | ﹤0.01% | 5567 |
|
|
2020
Q4 | $613K | Buy |
34,021
+5,653
| +20% | +$118K | ﹤0.01% | 4382 |
|
|
2020
Q3 | $547K | Sell |
28,368
-4,512
| -14% | -$102K | ﹤0.01% | 4269 |
|
|
2020
Q2 | $859K | Buy |
32,880
+20,666
| +169% | +$505K | ﹤0.01% | 3928 |
|
|
2020
Q1 | $218K | Buy |
12,214
+1,699
| +16% | +$45.9K | ﹤0.01% | 4628 |
|
|
2019
Q4 | $351K | Buy |
10,515
+710
| +7% | +$19.4K | ﹤0.01% | 4627 |
|
|
2019
Q3 | $233K | Buy |
9,805
+1,464
| +18% | +$47.9K | ﹤0.01% | 4867 |
|
|
2019
Q2 | $300K | Buy |
+8,341
| New | +$308K | ﹤0.01% | 4733 |
|
|
2019
Q1 | – | Sell |
-15,181
| Closed | -$653K | – | 6470 |
|
|
2018
Q4 | $653K | Sell |
15,181
-3,008
| -17% | -$135K | ﹤0.01% | 4169 |
|
|
2018
Q3 | $859K | Sell |
18,189
-682
| -4% | -$31.7K | ﹤0.01% | 4068 |
|
|
2018
Q2 | $939K | Buy |
18,871
+17,881
| +1,806% | +$1.04M | ﹤0.01% | 4040 |
|
|
2018
Q1 | $49K | Buy |
+990
| New | +$49.6K | ﹤0.01% | 5569 |
|
Other funds holding URGN
RI
KCM
JFG
PBA
ACA
Wells Fargo's URGN Position: Q1 2026 in Review
Wells Fargo reduced its UroGen Pharma (URGN) stake by 34% in Q1 2026, selling an estimated $569K and leaving 55,757 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #3728.
Wells Fargo first reported a position in URGN in Q1 2018 and has held it in 32 quarters since. The position peaked at $4.42M in Q2 2023. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.
- Wells Fargo held 55,757 shares of UroGen Pharma worth $1M as of Q1 2026.
- Wells Fargo sold 28,401 UroGen Pharma shares in Q1 2026, an estimated $569K.
- UroGen Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3728 holding.
- Wells Fargo first reported a position in UroGen Pharma in Q1 2018 and has held it in 32 quarters since.
- Wells Fargo's UroGen Pharma position peaked at $4.42M in Q2 2023.
- 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.